ATAI Life Sciences is a biotechnology company focused on developing innovative treatments for mental health conditions using psychedelics and related compounds. The company develops therapies for depression, anxiety, addiction, PTSD, and other psychiatric disorders. ATAI operates as a holding company with direct or indirect stakes in multiple clinical-stage biotech companies including Perception Neuroscience, Viridia Life Sciences, EmpathBio, and others. In November 2025, ATAI completed a strategic merger with Beckley Psytech Limited to form AtaiBeckley.
ATAI Life Sciences AG is publicly traded
IPO'd on June 22, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under ATAI.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2018
Employees
75–200
Total Funding
$282M
3 rounds
Total raised $282M across 3 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series D
Date
March 2021
Amount
$157M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| March 2021 | Series D | $157M | — | Christian Angermayer, Thiel Capital, Woodline Partners |
| November 23, 2020 | Series C | $125M | — | Apeiron Investment Group |
| March 27, 2019 | Series B | Not disclosed | — | Apeiron Investment Group, Subversive Capital |
Christian Angermayer
Founder and Chairman
Dr. Srinivas Rao
CEO and Co-Founder
Anne Johnson
Chief Financial Officer
Rob Conley
Chief Research & Development Officer
Gerd Kochendoerfer
Chief Operating Officer
Kevin Craig
Chief Medical Officer
Glenn Short
Chief Scientific Officer
Ryan Barrett
Chief Legal and Business Officer
Scott Braunstein
Vice Chairman and Lead Independent Director
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Compass Pathways
UK-based psychedelic biotech company developing COMPASS for treatment-resistant depression. ATAI holds 22.4% stake.
MindMed
Psychedelic biotech developing LSD and psilocybin-based treatments for mental health conditions; NASDAQ-listed competitor.
Perception Neuroscience
ATAI portfolio company focused on developing rapid-acting treatments for treatment-resistant depression.
Viridia Life Sciences
ATAI portfolio company focused on developing VLS-01 for treatment-resistant depression.
EmpathBio
ATAI portfolio company developing EMP-01 for social anxiety disorder with positive Phase 2 results reported in Q1 2026.
DemeRx
ATAI-affiliated company developing treatments in the psychedelic therapeutics space.
Yes, ATAI Life Sciences AG is publicly traded under the ticker symbol ATAI on the NASDAQ. The company went public in June 22, 2021.
ATAI Life Sciences AG trades under the ticker symbol ATAI on the NASDAQ. It began trading in June 22, 2021.
ATAI Life Sciences AG (ATAI on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker ATAI to place an order.
ATAI Life Sciences AG went public in June 22, 2021 via ipo. ATAI Life Sciences completed its NASDAQ IPO on June 22, 2021, at $15 per share, raising $225M and achieving a $2.3B post-money valuation. The company is a leader in psychedelic therapeutics and operates as a holding company with investments in multiple clinical-stage biotech firms. In November 2025, ATAI completed a strategic merger with Beckley Psytech to form AtaiBeckley, consolidating leadership in the psychedelic medicine space. The merged entity continues trading as ATAI on NASDAQ with an estimated market cap of $1.29B as of May 2026.
ATAI Life Sciences AG raised $282M across 3 disclosed funding rounds prior to its public listing.
ATAI Life Sciences AG was co-founded by Christian Angermayer, and Dr. Srinivas Rao in 2018.
ATAI Life Sciences AG is headquartered in Berlin, Germany.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.